Shots:
- Ipsen has entered into a definitive share purchase agreement to acquire all issued & outstanding shares of Memo Therapeutics, with closing expected in Q3’26
- As per the deal, Memo shareholders will receive €200M upfront at closing, with total consideration exceeding €700M upon achieving development, regulatory, & sales milestones. Assets & employees unrelated to potravitug will transfer to newly formed Memorises Bio before closing
- Acquisition will add potravitug, a monoclonal antibody against BKPyV, which is being evaluated in the P-II (SAFE Kidney II) trial for the treatment of BK polyomavirus-associated nephropathy in kidney transplanted pts
Ref: Globenewswire | Image: Memo Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
